Target Profile
```
Patient's age must be greater than or equal to 18 years.
Patient's gender must be female.
Patient must have active diagnosis of Breast cancer.
Patient must not have active diagnosis of Estrogen receptor positive tumor.
Patient must not have historical diagnosis of Progesterone receptor positive tumor.
Patient must have historical diagnosis of HER2-positive carcinoma of breast.
Patient must have a health evaluation score of ECOG performance status grade:Prid:Pt:^Patient:Nom:Observed less than or equal to 1.
Patient must not be pregnant.
Patient must not be breastfeeding.
Patient must not have active diagnosis of Metastasis to brain.
Patient must not have active diagnosis of Leptomeningeal sarcoma.
Patient must not have historical diagnosis of Congestive heart failure AND New York Heart Association Classification - Class II within less than or equal to 6 months.
Patient must not have historical diagnosis of Congestive heart failure AND New York Heart Association Classification - Class III within less than or equal to 6 months.
Patient must not have historical diagnosis of Congestive heart failure AND New York Heart Association Classification - Class IV within less than or equal to 6 months.
Patient must not have historical diagnosis of Heart attack within less than or equal to 6 months.
Patient must not have historical diagnosis of Interstitial lung disease.
Patient must not have historical diagnosis of Sarcoidosis.
Patient must not have historical diagnosis of Silicosis.
Patient must not have historical diagnosis of Idiopathic pulmonary fibrosis.
Patient must not have adverse event of Grade 2 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 3 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 4 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 5 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 2 Peripheral motor neuropathy.
Patient must not have adverse event of Grade 3 Peripheral motor neuropathy.
Patient must not have adverse event of Grade 4 Peripheral motor neuropathy.
Patient must not have adverse event of Grade 5 Peripheral motor neuropathy.
Patient must not have historical medication within drug class  INVESTIGATIONAL AGENTS within less than or equal to 4 weeks.
Patient must not have drug allergy to ingredient nab-paclitaxel.
Patient must not have drug allergy to ingredient gemcitabine.
Patient must not have drug allergy to drug class Platinum-based Drug.
Patient must not have drug allergy to drug class Nucleoside Analog.
Patient must not have historical diagnosis of HIV infection.
```
